RxDoctor Payments Data

John Rogers, MD

Adult Medicine · The Woodlands, TXNPI 1194828020

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,074 and has fallen 98.7% since, to $14 in 2025.

$2,266in general payments, 2019–2025

Across 92 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$466
  • Amgen$435
  • AbbVie$349
  • Novo Nordisk$220
  • Idorsia Pharmaceuticals US Inc$159
  • Inspire Medical Systems, Inc.$125
  • plus $512 from 14 others

What the payments were for

  • Food & beverage$2,266100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,266 in reported general payments places this provider in the 75th percentile of 98 adult medicine providers in Texas.

See all adult medicine providers in Texas

Medicare billing

Part B allowed, 2024
$5,817
Medicare patients
25
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab17$12,355
SynthroidLevothyroxine Sodium14$1,279
Rosuvastatin Calcium48$1,206
Testosterone Cypionate11$1,068
Estradiol (Twice Weekly)Estradiol12$1,062
Lidocaine11$802
Ezetimibe15$483
Bupropion XlBupropion Hcl12$428
Atorvastatin Calcium21$423
Gabapentin23$419
Nifedipine ErNifedipine18$390
Duloxetine Hcl29$342
Lisinopril27$326
Liothyronine Sodium11$284
ProgesteroneProgesterone, Micronized13$279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$349$1,27914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 98 adult medicine providers in Texas.

Other adult medicine in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →